In an announcement by the National Institute for Health and Care Excellence (NICE) it confirms that Zilucoplan (Zilbrysq) ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR ...

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published ...

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis.

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around.

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to diseas ...

Myasthenia gravis (MG) is an autoimmune disorder that affects how well your nerves and muscles communicate. Learn more about MG symptoms.

Generalized Myasthenia Gravis: Understanding the Role of FcRn Antagonists This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs ...

Andrea Divis was diagnosed with myasthenia gravis in 2018. Here, she shares how she educated herself and took back control of her health.